Congress Coverage: ASCO 2021 – Focus on Lung Cancer

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment.

June 11, 2021
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health

Faculty Chair

Corey J. Langer, MD, FACP

University of Pennsylvania, Philadelphia, PA, USA


Julie Brahmer, MD
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA

Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain

Marina Garassino, MD
University of Chicago Medicine, Chicago, Il, USA

David Jablons, MD
University of California San Francisco, San Francisco, CA, USA

Natasha Leighl, MD
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Lynette Sholl, MD
Dana-Farber Cancer Institute, Boston, MA, USA

David Spigel, MD
Sarah Cannon Cancer Center, Nashville, TN, USA

Sample Report

Start discovering the insights

View Report


  • Immunotherapy in Stage I–III NSCLC
  • Immunotherapy in Stage IV NSCLC
  • EGFR (Common Mutations): Resectable and Metastatic
  • EGFR (Exon 20 and Other Uncommon Mutations)
  • Oncogenic Fusions
  • Oncogenic Mutations
  • Other Targets in NSCLC/SCLC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.